312 related articles for article (PubMed ID: 34101631)
1. Patients with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for hepatitis C virus.
Guardigni V; Toschi A; Badia L; Rosselli Del Turco E; Salsi E; Cristini F; Sighinolfi L; Fabbri G; Massari M; Cuomo G; Viale P; Verucchi G;
AIDS; 2021 Oct; 35(12):1967-1972. PubMed ID: 34101631
[TBL] [Abstract][Full Text] [Related]
2. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
5. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
7. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
8. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
9. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL;
Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
11. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
Sanduzzi-Zamparelli M; Mariño Z; Lens S; Sapena V; Iserte G; Pla A; Granel N; Bartres C; Llarch N; Vilana R; Nuñez I; Darnell A; Belmonte E; García-Criado A; Díaz A; Muñoz-Martinez S; Ayuso C; Bianchi L; Fuster-Anglada C; Rimola J; Forner A; Torres F; Bruix J; Forns X; Reig M
J Hepatol; 2022 Apr; 76(4):874-882. PubMed ID: 34856322
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
13. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
14. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
[TBL] [Abstract][Full Text] [Related]
16. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
Sangiovanni A; Alimenti E; Gattai R; Filomia R; Parente E; Valenti L; Marzi L; Pellegatta G; Borgia G; Gambato M; Terreni N; Serio I; Belli L; Oliveri F; Maimone S; Brunacci M; D'Ambrosio R; Forzenigo LV; Russo FP; Rumi M; Barone M; Fracanzani AL; Raimondo G; Giannini EG; Brunetto MR; Villa E; Biganzoli E; Colombo M; Lampertico P
J Hepatol; 2020 Sep; 73(3):593-602. PubMed ID: 32243959
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.
Rinaldi L; Perrella A; Guarino M; De Luca M; Piai G; Coppola N; Pafundi PC; Ciardiello F; Fasano M; Martinelli E; Valente G; Nevola R; Monari C; Miglioresi L; Guerrera B; Berretta M; Sasso FC; Morisco F; Izzi A; Adinolfi LE
J Transl Med; 2019 Aug; 17(1):292. PubMed ID: 31462268
[TBL] [Abstract][Full Text] [Related]
18. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
[TBL] [Abstract][Full Text] [Related]
19. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
20. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
